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 Glaucoma is the leading cause of irreversible blindness
and the second leading cause of blindness after cataract, af-
fecting 66 million people worldwide [1]. Glaucoma is a het-
erogeneous group of progressive optic neuropathies charac-
terized by an excavation of the optic disc and progressive al-
teration of the visual field [2]. High intraocular pressure (IOP),
defined as being above 21 mmHg, in both eyes and a positive
family history for glaucoma are commonly associated risk
factors. Based on the age of onset and other clinical features,
glaucoma has been classified into primary congenital glau-
coma (PCG), juvenile-onset open-angle glaucoma (JOAG),
and adult-onset primary open-angle glaucoma (POAG). PCG
manifests at birth or in early infancy (up to 3 years of age). Its
phenotype is characterized by elevated IOP, corneal edema,
enlargement of the globe (buphthalmos), epiphora, photopho-
bia, and blepharospasm. PCG occurs as a result of develop-
mental anomalies of the anterior chamber angle that prevent
drainage of the aqueous humor, thereby elevating IOP. PCG
is most commonly inherited as an autosomal recessive trait.
JOAG is characterized by early onset (at 10-35 years of age)
and autosomal dominant inheritance with high penetrance.
POAG occurs after the age of 35 years and is the most com-
mon form of glaucoma.
In a majority of cases, glaucoma does not follow a clear-
cut inheritance pattern. However, clustering of multiple af-
fected individuals within families suggests that it has a ge-
netic basis. Linkage analyses have identified 23 loci (GLC1A-
GLC1L, GLC3A-GLC3B, 2p14, 2q33-q34, 5q22.1-q32,
10p12-p13, 14q11, 14q21-q22, 17p13, 17q25, and 19q12-q14)
for different forms of glaucoma [3-10]. However, only four
genes (MYOC/TIGR, CYP1B1, OPTN, and WDR36) have been
identified so far [4,11-13]. The myocilin/trabecular meshwork-
induced glucocorticoid response protein (MYOC/TIGR) gene,
located at the GLC1A locus on chromosome 1q24.3-q25.2,
has been shown to cause glaucoma in 2-4% of POAG cases
[14]. The cytochrome P450 (CYP1B1) gene, located at the
GLC3A locus on chromosome 2p22-p21, has been shown to
cause PCG, JOAG, and POAG [2,12,15]. In a large family in
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Methods: Blood samples were obtained from individuals for DNA isolation. A combination of polymerase chain reac-
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Results: Three previously known mutations (Pro193Leu, Glu229Lys, and Arg368His) and one novel (Met292Lys) muta-
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The absence of allele sharing for D2S177, D2S1346, D2S2974, and D2S2331 markers and three intragenic CYP1B1 SNPs
in patients suggested multiple origins for the Glu229Lys and Arg368His variants. Two of 251 (0.8%) patients had the
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Taken together, 3.59% (9/251) of our POAG patients had mutations in the CYP1B1, MYOC, and OPTN genes.
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which MYOC-linked POAG segregated, a heterozygous mu-
tation in CYP1B1 was associated with early onset of the dis-
ease, indicating that a CYP1B1 mutation might behave as a
modifier of the MYOC gene [15]. The optineurin (OPTN) gene,
located at the GLC1E locus on chromosome 10p14-p15, has
been shown to cause normal tension glaucoma (NTG), a sub-
type of POAG [13]. The WD repeat-containing protein 36
(WDR36) gene, located at the GLC1G locus on chromosome
5q21.3-q22.1, has been shown to be mutated in POAG [4].
Glaucoma is a treatable disease if detected early. There-
fore, development of an accurate test for the detection of
presymptomatic carriers at risk is important for the manage-
ment of glaucoma. To this end, a few studies have been car-
ried out to assess the roles of the MYOC [16-19], CYP1B1
[20], and OPTN [21-22] genes in the etiology of Indian POAG
patients from different parts of the country. We have reported
the genetic analysis of glaucoma in a large south Indian pedi-
gree [18]. Moreover, there is no comprehensive study pub-
lished to date that assesses the roles of three known glaucoma-
causing genes (CYP1B1, MYOC, and OPTN) in the same set
of Indian POAG patients. In this study, we report mutation
analysis of the CYP1B1, MYOC, and OPTN genes in 251 In-
dian POAG patients from the south Indian state of Karnataka.
The OPTC (opticin) gene encodes a protein that is a mem-
ber of the small leucine-rich repeat protein (SLRP) family,
and is located on chromosome 1q31-q32 within an age-re-
lated macular degeneration (AMD) susceptibility locus [23].
Because of its protein profile in different parts of the eye, such
as the iris, trabecular meshwork/ciliary body, retina, vitreous,
and optic nerve, Friedman et al. [23] screened OPTC for mu-
tations in individuals with POAG, NTG, and AMD. They failed
to find any mutation in this gene. To rule out the OPTC gene
as a glaucoma gene, we screened this gene in our POAG data
set. The results of our analysis are presented herein.
METHODS
Patients:  A total of 251 patients with adult-onset POAG were
evaluated at the Minto Ophthalmic Hospital, and Bangalore
West Lions Superspecialty Eye Hospital. Both hospitals are
located in the city of Bangalore, Karnataka. The patients were
natives of Karnataka and spoke the south Indian Kannada lan-
guage. They ranged in age from 45 to 65 years. Of the 251
patients, 116 patients received the diagnosis of POAG based
on the presence of characteristic glaucomatous optic neuropa-
thy and defects in visual fields. The remaining 135 patients
were given the diagnosis of glaucoma based on glaucomatous
optic neuropathy only, as visual field defects could not be as-
sessed in these patients due to an advance stage of glaucoma.
IOP was more than 21 mmHg in 198 patients. The remaining
53 patients had NTG with IOP below 21 mmHg and signifi-
cant optic disc damage and visual field defects at the time of
diagnosis. All patients had open-angles (Shafer grade greater
than III) on gonioscopy and no other eye or systemic abnor-
malities. Patients with secondary causes of glaucoma (e.g.,
uveitis, steroid-induced, or trauma) were excluded from this
study. We recruited 100 normal controls, also from Karnataka
and with the same linguistic background, through several eye
care camps. Their ages ranged from 45 to 75 years. All par-
ticipants went through a detailed clinical examination and were
found to have no signs or symptoms of glaucoma or any other
eye disease. Controls did not have any family history of glau-
coma. Informed consent was obtained from each patient. This
study followed the guidelines of the Indian Council of Medi-
cal Research, New Delhi.
Molecular study:  Three to five ml of peripheral blood
was collected from each individual in Vacutainer EDTA™
tubes (Beckton-Dickinson, Franklin Lakes, NJ). Genomic
DNA was isolated from blood samples using a Wizard® ge-
nomic DNA extraction kit (Promega, Madison, WI). Muta-
tion analyses of the four genes were carried out using a com-
bination of PCR-SSCP (polymerase chain reaction-single
strand conformation polymorphism) and DNA sequencing
techniques. For PCR-SSCP, primer sets were designed for the
CYP1B1, MYOC, OPTN, and OPTC genes, which covered
their entire coding regions and intron-exon junctions. The ref-
erence mRNA sequences for the CYP1B1, MYOC, OPTN, and
OPTC genes used were U03688, NM_000261, AF420371, and
NM_014359, respectively. The genomic sequences for these
genes were retrieved from the UCSC Genome Bioinformatics
site. Primer details are shown in Table 1 Since abnormalities
in WDR36 alone are not sufficient to cause POAG [24], we
have not screened this gene for mutations in our POAG
samples. In the future, we plan to screen this gene for muta-
tions in our samples. PCR was carried out in a 25 µl reaction
volume containing 50-100 ng of genomic DNA, 50 ng of each
primer, 0.25 µl of alpha P32-dCTP (3,000 Ci/mmole;
PerkinElmer, Wellesley, MA), 0.2 mM of each dNTP, and 1 U
of Taq DNA polymerase (Bangalore Genei™, Bangalore, In-
dia) in a standard buffer supplied by the vendor. PCR was
carried out in a Thermal Cycler PTC150 (MJ Research,
Watertown, MA) under the following conditions: an initial
denaturation at 95 °C for 2 min was followed by 35 cycles at
95 °C for 30 s, 55-72 °C for 30 s, 72 °C for 1 min with a final
extension at 72 °C for 5 min. Following PCR-SSCP, the gels
were dried and subjected to Phosphor Image analysis (Fuji,
Kanagawa, Japan). For sequencing, PCR was carried out as
aforedescribed but without including alpha P32-dCTP in the
reaction mixture. PCR amplified products were purified us-
ing Auprep™ PCR Purification Columns (Invitrogen, Delhi,
India) and sequenced on an ABI PRISM A310 automated se-
quencer (PE Biosystems, Foster City, CA). Since we did not
identify the MYOC Gln48His mutation reported from India
earlier [19] in our samples by PCR-SSCP analysis, we used
allele-specific PCR to screen the samples for the presence of
this mutation. The sequence of the common forward primer
for allele-specific PCR is as follows: 5'-TGC AAT GAG GTT
CTT CTG TGC ACG-3'. The sequences of the reverse allele-
specific primers are as follows: 5'(mutant allele)-GAC TGG
CCA CAC TGA AGG TAT AA-3' and 5'(wild-type allele)-
GAC TGG CCA CAC TGA AGG TAT AC-3'. A 190 bp
amplicon was generated with common forward and wild-type/
mutant allele primers. Following detection of this mutation in
patient samples, PCR products were sequenced to confirm the
presence of the mutation. The MYOC-83G>A promoter poly-
668morphism was studied by PCR-SSCP analysis. Primer se-
quences for this polymorphism are as follows: forward 5'-CAG
CCT CAC GTG GCC ACC TCT GTC-3' and reverse 5'-AGG
CCC AAA GCT GCA GCA ACG TGC-3'. These primers
amplify a 196 bp amplicon. In order to see whether there could
be a common origin of a specific CYP1B1 mutation, all pa-
tients with the mutation were genotyped with four
microsatellite markers from the CYP1B1 candidate region and
three intragenic CYP1B1 single nucleotide polymorphisms
(SNPs). The order of markers with respect to CYP1B1 is as
follows: D2S177-D2S1346-CYP1B1-D2S2974-D2S2331
(taken from the UCSC Genome Bioinformatics site).
RESULTS & DISCUSSION
 Analysis of the entire coding region of the CYP1B1 gene in
POAG patients revealed four different mutations (c.578C>T/
Pro193Leu, c.685G>A/Glu229Lys, c.875T>A/Met292Lys,
and c.1103G>A/Arg368His) in 10.76% (27/251) of patients
(Table 2). Three mutations; Pro193Leu, Glu229Lys, and
Arg368His, have been reported earlier in PCG patients from
different populations [25-27]. The fourth mutation, Met292Lys,
is a novel one in exon 2 and fulfills the criteria of a mutation
since the methionine residue is conserved across species from
human to carp (Figure 1A) and was not found in 97 controls
(data not shown). Only patients 119 and 179 were compound
heterozygous for Met292Lys/Arg368His and Pro193Leu/
Glu229Lys, respectively (Table 2). The remaining patients
were heterozygous for the Pro193Leu, Glu229Lys, Met292Lys,
and Arg368His mutations (Table 2). Melki et al. [2] found
that 4.6% (11/236) of French patients with early-onset POAG
have mutations in CYP1B1. They have reported the Glu229Lys
mutation in a heterozygous state. Colomb et al. [27] found
that 6.45% (2/31) of French PCG patients have the Glu229Lys
mutation in a heterozygous state. Acharya et al. [20] observed
that 4.5% (9/200) of patients with JOAG from the eastern In-
dian state of West Bengal have mutations in CYP1B1. The
Glu229Lys and Arg368His mutations were found in a heterozy-
gous state, and these mutations were not present in 100 ethni-
cally matched controls [20].
Vincent et al. [15] reported the Arg368His mutation in a
heterozygous state along with the MYOC Gly399Val muta-
tion in an east Indian/Guyanese family with early-onset glau-
coma. Of 30/251 patients with mutations in our samples, 13
patients (5.2%) had the Glu229Lys mutation and 10 patients
(3.98%) had the Arg308His mutation (Table 2). In order to
see whether these mutations were present in normal controls,
we screened 100 normal controls. The Glu229Lys and Arg368
mutations were found with frequencies of 5% and 2%, respec-
tively, in normal controls (data not shown), suggesting that
these mutations might be polymorphic variants in our popula-
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TABLE 1. DETAILS OF PRIMER SETS USED IN THE PCR-SSCP ANALYSIS
OF THE CYP1B1, MYOC, OPTN, AND OPTC GENES.
                                                         Amplicon     AT
 Gene    Exon          Primer sequence (5'-3')           size (bp)   (°C)
------   ----   --------------------------------------   ---------   ----
CYP1B1
           2    CY2AF:TGTCTCTGCACCCCTGAGTGTCA              264        67
                CY2AR:GAGGTGAGCCGCCTGGCCCAC
           2    CY2BF:TGCTGAGGCAACGGAGGCGGCA               211        68
                CY2BR:TGCACCAGGGCCTGGTGGATGG
           2    CY2CF:TCCAGATCCGCCTGGGCAGCTG               262        67
                CY2CR:CTCAGCACGTGGCCCTCGAGGA
           2    CY2DF:CAGCATGATGCGCAACTTCTTCAC             254        64
                CY2DR:GCGCCCGAACTCTTCGTTGTGGC
           2    CY2EF:TGCCGCTACAGCCACGACGACC               261        64
                CY2ER:GAGGATAAAGGCGTCCATCATGTCG
           2    CY2FF:GACAAGTTCTTGAGGCACTGCGAA             267        66
                CY2FR:TCAGAGGAGAAAAGACCTGGCCCA
           3    CY3AF:GCTCACTTGCTTTTCTCTCTCCAC             255        60
                CY3AR:CCACAGTGTCCTTGGGAATGTGGTA
           3    CY3BF:TCACTATTCCTCATGCCACCACTG             277        60
                CY3BR:TGAGCCAGGATGGAGATGAAGAGA
           3    CY3CF:AAAGGCGGTGCATTGGCGAAGAAC             291        60
                CY3CR:TTACTCCTCATCTCCGAAGATGTGA
MYOC
           1    TG1AF:AAACCTCTCTGGAGCTCGGGCA               248        60
                TG1AR:TATACTGGCATCGGCCACTCTGG
           1    TG1BF:GCCTGCCTGGTGTGGGATGTGG               255        64
                TG1DBR:GGCAGCCTGGTCCAAGGTCAATTGG
           1    TIG1CF:GGAGGCCACCAAAGCTCGACTCA             212        60
                TG1CR:TCTCTTCCTCCAGAACTGACTTGTC
           1    TG1DF:CCAAACCAGAGAGTTGGAGACTGC             256        62
                TG1DR:AGCCATATCACCTGCTGAACTCAGA
           2    TG2F:CTCAACATAGTCAATCCTTGGGCCA             244        60
                TG2R:GACATGAATAAAGACCACGTGGGCA
           3    TIGR1DF:CAAGTATGGTGTGTGGATGCGAGA           205        64
                TIGR1R:GCTCCCCGAGTACACCACAGCA
           3    TIGR1F:GCCAAGCTTCCGCATGATCATTG             231        60
                TIGR1DR:GTGCCAACTGTGTCGATTCTCCA
           3    TIGR2DF:CCTTCTAAGGTTCACATACTGCCTAG         270        66
                TIGR2DR:AATGGCACCTTTGGCCTCATCGGTG
           3    TIGR3F:ACATTGACTTGGCTGTGGATGAAG            267        64
                TIGR3R:ATGGGATGGTCAGGGTCTTGCTG
           3    TIGR4F:ACCTCAGCAGATGCTACCGTCAA             216        64
                TIGR4R:CCATTGCCTGTACAGCTTGGAGG
OPTN
           4    OPTN4aF:AATCGCCAATGGGTTTGTGGGA             198        64
                OPTN4aR:ACGTGTCCAGGTTTGGGTGGGC
           4    OPTN4bF:AGGAGGACAGCCCCAGTGAAAGCAC          193        72
                OPTN4bR:AGGGATGGCATTTCTTGCAGGCCCA
           5    OPTN5F:CACTTTCCTGGTGTGTGACTCCATC           280        64
                OPTN5R:AAAAAACAACATCACAATGGATCGGTC
           6    OPTN6F:CAGCCTTAGTTTGATCTGTTCATTCAC         284        60
                OPTN6R:CCAGGGGAGGCTTTATAGTTTGCTC
           7    OPTN7F:TGGAAGCTTCCTTGGGTTGCATGTC           275        65
                OPTN7R:AACATTTGACCTCCGGTGACAAGCA
           8    OPTN8F:GGTTACTCTCTTCTTAGTCTTTGGAA          286        60
                OPTN8R:GTATCTTAATTATATCTCAGGAAAGCTG
           9    OPTN9F:TTCTCTTAAAGCCAAAGAGAAAGTAAC         232        55
                OPTN9R:CACAAG ATTTGAATTCAGTGGCTGGA
          10    OPTN10F:GTTTAATGTCAGATGATAATTGTACAGA       223        58
                OPTN10R:CTTTGTAAAAATGTATATTTCAAAGGAGG
          11    OPTN11F:CGTAAAGGAGCATTGTTTATCCTCA          264        60
                OPTN11R:CAATCTGTATAAAAAGGCGATTCTCC
          12    OPTN12F:GAAGGTTGGGAGGCAAGACTATAAG          224        60
                OPTN12R:CAACAGTTTCTGTTCATTACTAGGCTA
          13    OPTN13F:CAGGCAGAATTATTTCAAAACCATTTCTAG     252        60
                OPTN13R:CAGGGCTGGCCTCGCTCAGCTGG
          14    OPTN14F:TGCATTCATCTAGGTACTAAGTTCTG         229        60
                OPTN14R:TCTACGGCCATGCTGATGTGAGCT
          15    OPTN15F:GTCTGCTCAGTGTTGTCATGTTTCG          243        60
                OPTN15R:GAATCCATTGTAGAGAATGAAGTGGAA
          16    OPTN16F:CAAGTGAAACAAACACAACTGCCTG          227        60
                OPTN16R:CTGACATTTACCAACAGTTTTGGGGA
OPTC
           2    OP2aF:CACTCTGGAGAGCCTGTCCCTCAGA            227        64
                OP2aR:GAACTTCAAAGGAATCGCCTTCCCTG
           2    OP2bF:CAGGAGACAGGGACAGCTTCTCTC             236        64
                OP2bR:CTCCCAGTGTCATGCAGGGAATGTA
           3    OP3F:TTTGTGCAAAAGCTGGGCTACTGTG             230        60
                OP3R:GCCTATGACCTAGGGATATTGCGA
           4    OP4F:GCCCCAGAGGCTAAAGAGATCTCC              265        64
                OP4R:CAGGGTGGCTGCATATGCCTGC
           5    OP5F:AAAGATAGTGTGTTCTGGTTTCTCTC            296        64
                OP5R:GTGGTGGAGGTGATAGATAGTGGA
           6    OP6F:CCAACAGGACCCACCAGCCTCCTA              209        64
                OP6R:CTGCTCCTGGTATCTAACTTCCATCC
           7    OP7F:GGCAGAGCCTCTTGGTGAGGCTCA              276        64
                OP7R:GGCCCATGCCTGCATGGTCCTTG
Note that primer sets CY2AF/CY2AR, OPTN4aF/OPTN4aR, and OPTN7F/OPTN7R work with 5% DMSO and 1.5 mM magnesium chlo-
ride. Primer sets CY2BF/CY2BR, CY2CF/CY2CR, CY2DF/CY2DR, and CY2EF/CY2ER work with 5% DMSO and 1 mM magnesium
chloride. Primer set TG1BF/TG1DBR works with 1 mM magnesium chloride. The rest of the primer sets work with 1.5 mM magnesium
chloride. Exon 1 of CYP1B1, exons 1, 2, and 3 of OPTN, and exon 1 of OPTC were not screened for mutations as they are non-coding. AT,
annealing temperature.
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TABLE 2. PREVIOUSLY KNOWN AND NOVEL MUTATIONS DETECTED IN THE CYP1B1, MYOC, AND OPTN GENES IN PRIMARY OPEN-ANGLE GLAU-
COMA PATIENTS
Shown are details of 30 primary open-angle glaucoma (POAG) patients with previously known and novel mutations in the CYP1B1, MYOC,
and OPTN genes. Since the Glu229Lys and Arg368His mutations were found in normal controls with frequencies of 5% and 2%, respectively,
these mutations might be polymorphic variants in our population. By excluding these mutations, the frequency of patients with mutations in
three glaucoma-causing genes is 3.59% (9/251). In the table, * indicates a novel mutation; + identifies wild-type alleles; # indicates a family
history of glaucoma; other cases are sporadic. The following abbreviations were used: normal tension glaucoma (NTG), right eye (RE), left
eye (LE), both eyes (BE), perception of light negative (PL-ve), and cup to disc (CD). The age of onset and diagnosis are in years.
670tion. The presence of the Arg368His mutation in controls is
not surprising as Melki et al. [2] discovered 2.13% (1/47) of
French controls with this mutation. The Glu229Lys and
Arg368His mutations were the most common mutations in
Indian PCG patients with frequencies of 16.22% (6/37) and
59.46% (22/37), respectively [28]. However, ethnically
matched population screening of 140 chromosomes for the
CYP1B1 mutations showed 6.4% and 0.7% carriers for the
Glu229Lys and Arg368His mutations, respectively [28]. The
other known mutation, Pro193Leu, was not present in 100
normal controls (data not shown). In order to determine
whether the Glu229Lys variant in 13 patients could have a
common origin, all patients were genotyped with four
microsatellite markers (D2S177-D2S1346-CYP1B1-
D2S2974-D2S2331) and three intragenic CYP1B1 SNPs. An
absence of allele sharing for the markers in patients suggested
that Glu229Lys has multiple origins (Table 3). A similar re-
sult was obtained for the Arg368His mutation (Table 3).
In addition to mutations, nine CYP1B1 population vari-
ants and polymorphisms were also identified in our samples,
including two novel SNPs (Table 4). It is interesting to note
that c.142C>G (Arg48Gly) and c.355G>T (Ala119Ser) oc-
curred at a high frequency and were in complete linkage dis-
equilibrium (Table 4). Similarly, c.1294G>C (Val432Leu) and
c.1347T>C (Asp449Asp) also occurred at a high frequency
and were in complete linkage disequilibrium (Table 4). Inter-
estingly, c.142C>G (Arg48Gly) and c.355G>T (Ala119Ser)
always occurred with c.1294G>C (Val432Leu) and c.1347T>C
(Asp449Asp) in patients. Similar results were obtained in
JOAG patients and normal controls from the east Indian state
of West Bengal (Table 5) [20]. The significance of this phe-
nomenon is not clear at present.
Analysis of the MYOC gene revealed that 2/251 (0.8%)
patients had the Gln48His mutation in a heterozygous state.
This mutation was not present in 100 normal controls (data
not shown). No other mutation was detected in our samples.
The Gln48His mutation has been detected in 4/200 (2%) POAG
patients in a heterozygous state from West Bengal [19]. This
mutation has also been detected in 5/200 (2.5%) PCG patients
[19]. Previously, we detected a novel Pro274Arg mutation in
a four-generation family with members affected with JOAG
and POAG, and with one severely affected patient being ho-
mozygous for the mutation [18]. Overall, the frequency of
MYOC mutations has been found to be 2-4% in different popu-
lations [14]. Kanagavalli et al. [17] noted 1.87% (2/107) of
patients with POAG from the south Indian state of Tamilnadu
who had mutations in the MYOC  gene. However,
Mukhopadhyay et al. [16] discovered a higher frequency
(7.14% or 4/56) of POAG patients from West Bengal with
MYOC mutations. This could be a statistical anomaly due to a
small sample size or a true pattern representative of different
geographic origins.
The MYOC promoter polymorphism at -83G>A was ini-
tially reported from Western countries ([14,29] Table 5). This
polymorphism has been also observed in Hong Kong and the
Philippines [30,31]. Alward et al. [29] suggested that it is un-
likely to be a disease-causing mutation. Since this polymor-
phism was detected in many countries, we wanted to deter-
mine its prevalence in our patient and control samples. We did
not find any significant difference in the frequency of -83G>A
between POAG samples and controls (76.72% in POAG ver-
sus 76.53% in controls; Table 4). This is similar to the earlier
report from West Bengal by Mukhopadhyay et al. [16]. Inter-
estingly, -83G>A is in linkage disequilibrium with Arg76Lys
©2007 Molecular Vision Molecular Vision 2007; 13:667-76 <http://www.molvis.org/molvis/v13/a73/>
Figure 1. Mutation analysis of
the CYP1B1 and OPTN genes.
A: The left panel shows a se-
quencing chromatogram from
patient 119 who had a novel
mutation c.875T>A
(Met292Lys) in exon 2 of
CYP1B1, and the right panel
shows conservation of the me-
thionine residue across species.
B: The left panel presents a
sequencing chromatogram
from patient 30 who had a
novel mutation c.915C>G
(Thr202Arg) in exon 7 of
OPTN, and the right panel
shows conservation of the
threonine residue across spe-
cies. Arrows mark positions of
nucleotide changes and con-
served amino acid residues.
671both in patients and controls (Table 4 and Table 5), suggesting
that the -83G>A polymorphism is not a risk factor for devel-
oping glaucoma in Indians. Taken together, our observations
suggest that mutations in MYOC gene may not be a major
factor in the appearance of the POAG phenotype in India.
Mutation analysis of the entire OPTN gene revealed that
one patient (0.40%) was heterozygous for a novel mutation,
Thr202Arg (c.915C>G) in exon 7 (Figure 1B, Table 2). This
mutation fulfills the criteria of a mutation because it is not
present in 93 controls (data not shown) and the threonine resi-
due is conserved in human, macaque, mouse, and rat (Figure
1B). Sripriya et al. [22] recently screened the OPTN gene in
100 high tension glaucoma patients from another south In-
dian state, Tamilnadu, and did not detect any mutation.
Mukhopadhyay et al. [21] screened the entire coding region
of this gene and detected 6/200 (3%) POAG patients from
West Bengal, who were heterozygous for the Arg545Gln mu-
tation in exon 16. As observed in other populations [32-36],
the present observation also suggests that OPTN mutations
are rare in POAG patients. A total of eight mutations
(Glu50Lys, c.691-692insAG, Arg545Gln, Ala336Gly,
Ala377Thr, His26Asp, His486Arg, and Glu104Asp) have been
reported in the OPTN gene from different populations, includ-
ing the His486Arg mutation in a JOAG patient [13,21,32-36].
Interestingly, one of the three mutations, Arg545Gln
(c.1944G>A), reported by Rezaie et al. [13], has been detected
in similar frequencies in Japanese glaucoma patients and con-
trol subjects [37]. Alward et al. [38] commented that the
Arg545Gln variation is likely to be a nondisease-causing poly-
morphism. With the Thr202Arg mutation identified in this
study, the total number of OPTN mutations, excluding
Arg545Gln, reaches eight.
Rezaie et al. [13] initially reported that Met98Lys
(c.603T>A) is a risk-associated alteration (risk factor) for de-
veloping glaucoma. They found this variant in both affected
individuals and controls, but it was more common in affected
individuals than in controls (13.6% versus 2.1%). Alward et
al. [38] and Fuse et al. [33] showed a significant association
between Met98Lys and glaucoma in Japanese patients. On the
other hand, Toda et al. [37] found similar frequencies of
Met98Lys in Japanese glaucoma patients and controls. Inter-
estingly, Met98Lys has been shown to be a polymorphic vari-
ant in German, French, and Moroccan patients [35,39]. Sripriya
et al. [22] did not detect Met98Lys in 100 controls, although it
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TABLE 3. GENOTYPES AT FOUR MICROSATELLITE MARKERS FLANKING THE CYP1B1 CANDIDATE REGION AND THREE INTRAGENIC CYP1B1 SINGLE
NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH GLU229LYS AND ARG368HIS VARIANTS
Each number under a microsatellite marker column represents an allele. As can be seen from the genotypes at four microsatellite marker loci,
some patients with either of the variants did not share alleles. For example, patients 168 and 179 with Glu229Lys did not share alleles at
D2S177, D2S1346, and D2S2331. Although single nucleotide polymorphisms (SNPs) are less polymorphic than microsatellite markers,
patients 54 and 73 did not share alleles at c.142C>G. Similarly, patients 7 and 38 with Arg368His did not share alleles at D2S177, D2S1346,
and D2S2331. However, alleles at three SNP loci were not useful to determine nonsharing of alleles for Arg368His. Overall, the results suggest
multiple origins for both variants.
672was present in 7/170 (4.1%) POAG and 3/50 (6%) NTG pa-
tients from Tamilnadu. However, a statistical analysis did not
show any significant correlation with clinical parameters [22].
In another study by Mukhopadhyay et al. [21], the frequency
of Met98Lys was found to be 11% and 5.5% in POAG and
controls from West Bengal, respectively. Sripriya et al. [22]
found Met98Lys in 6% of NTG patients, whereas
Mukhopadhyay et al. [21] failed to find it in NTG patients. In
our dataset, the frequency of this variant was found to be similar
in our POAG samples and controls (7.97% in POAG versus
7.29% in controls; Table 4), suggesting that it may not be a
risk factor for developing glaucoma in Indian populations.
Mutation analysis of the OPTC gene did not detect any
mutation in our POAG samples. Screening of the OPTC gene
was carried out in POAG cases by Friedman et al. [23]. The
Leu268Pro polymorphism, identified by Friedman et al. [23]
in 6/87 (6.9%) of POAG/NTG patients and in 8/55 (14.55%)
of controls (Table 5), was found in 31/251 (12.35%) of our
POAG samples (Table 4). Another synonymous codon change
Leu270Leu, identified by Friedman et al. [23] in 2/55 (3.66%)
of controls (Table 5), was also detected in 5/251 (1.99%) of
our POAG samples (Table 4).
In summary, 3.59% (9/251) of our POAG patients had
mutations in the CYP1B1, MYOC, and OPTN genes. Two pre-
viously known CYP1B1 mutations, Glu229Lys and Arg368His,
were found in similar frequencies in POAG patients and con-
trols, suggesting that these mutations might be polymorphic
variants in our population. A similar situation exists for the
CYP1B1 Ala443Gly mutation, first reported by Melki et al.
[2] in French patients, and was found to be a polymorphic
variant in an Ethiopian population with a frequency of 7%
[40]. No association was found between the OPTN Met98Lys
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TABLE 4. POLYMORPHISMS AND POPULATION VARIANTS OBSERVED IN THE CYP1B1, MYOC, OPTN, AND OPTC GENES IN PRIMARY OPEN-ANGLE
GLAUCOMA PATIENTS AND CONTROLS
Shown are the frequencies of polymorphisms and population variants in the CYP1B1, MYOC, OPTN, and OPTC genes seen in primary open-
angle glaucoma (POAG) patients and controls. In the table, * indicates a risk factor, ** notes a novel single nucleotide polymorphism (SNP),
and # highlights two polymorphisms, -83G>A and Arg76Lys, that were detected in high frequencies in 116 patients and thus were not screened
in the remainder of the 251 patients.
673variant and glaucoma. Mutations in MYOC and OPTN are rare
in Indian POAG patients. This is the first study to document
the prevalence of mutations in three glaucoma-causing genes
in the same set of Indian POAG patients. Our study suggests
that mutations in these genes are rare in Indian POAG pa-
tients.
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